We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Hospital In-Patient Insulin Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00135070
Recruitment Status : Terminated (No documentation with MHRA to support clinical trial of a medicinal product.)
First Posted : August 25, 2005
Last Update Posted : May 1, 2007
Information provided by:
The Royal Bournemouth Hospital

Brief Summary:
Hyperglycaemia has been shown to increase morbidity and mortality in patients with critical illness, myocardial infarction and stroke. This study aims to look at patients with hyperglycaemia and reduce their blood sugar levels using differing combinations of subcutaneous and intravenous insulin.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Detemir Phase 4

Detailed Description:
This is a randomised trial involving patients with type II diabetes who are brought into the hospital with a problem other than a diabetic emergency. Patients will be included, who have a blood sugar > than 17mmols. They will be randomised to one of two groups and either given intravenous or subcutaneous insulin. Outcome measures are length of stay, glucose control and comparison of the two regimens. Cost implications will also be analysed.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Study Comparing Continuous Intravenous Insulin Infusion With Subcutaneous Insulin Analogues in Hospitalised Patients With Type II Diabetes and Hyperglycaemia
Study Start Date : July 2005
Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hyperglycemia
Drug Information available for: Insulin
U.S. FDA Resources

Primary Outcome Measures :
  1. Glucose control

Secondary Outcome Measures :
  1. Length of stay

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type II diabetes
  • Blood glucose > 17mmols

Exclusion Criteria:

  • Type I diabetes
  • Hyperosmolar non-ketotic coma (HONK)
  • Diabetic ketoacidosis (DKA)
  • Myocardial infarction (MI)
  • Vomiting

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00135070

United Kingdom
The Royal Bournemouth Hospital
Bournemouth, Dorset, United Kingdom, BH7 7DW
Sponsors and Collaborators
The Royal Bournemouth Hospital
Principal Investigator: David Kerr, Doctor The Royal Bournemouth Hospital

ClinicalTrials.gov Identifier: NCT00135070     History of Changes
Other Study ID Numbers: H.P.I.1
First Posted: August 25, 2005    Key Record Dates
Last Update Posted: May 1, 2007
Last Verified: April 2007

Keywords provided by The Royal Bournemouth Hospital:
Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs